ClinicalTrials HQ

Syndax Pharmaceuticals

Syndax Pharmaceuticals

Explore linked clinical trials.

16 results · Page 1 of 1

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationHemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myeloid leukemia, neoplasmRecruitingPhase 1 / Phase 22026-10-09NCT04065399
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 32026-09-25NCT07211958
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 1 / Phase 22026-09-23NCT05360160
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 1 / Phase 22026-09-18NCT06284486
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmActive, not recruitingPhase 12026-09-16NCT06226571
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesHemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, leukemia, neoplasmRecruitingPhase 22026-09-11NCT06229912
Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPreviously Untreated Relapsed Refractory Acute Myeloid LeukemiaRecruitingPhase 2 / Phase 32026-09-03NCT03013998
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasmNot yet recruitingPhase 12026-08-12NCT07283640
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myeloid leukemia, neoplasmRecruitingPhase 12026-08-03NCT06177067
Revumenib in Patients With MyelofibrosisHemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosisNot yet recruitingPhase 1 / Phase 22026-07-29NCT07734077
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasDisease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-07-22NCT03179930
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 22026-06-16NCT04710576
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorderActive, not recruitingPhase 22026-03-27NCT06132256
Revumenib in Combination With 7+3 + Midostaurin in AMLHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 12026-03-25NCT06313437
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 22025-10-15NCT03978624
High Dose IL 2 and Entinostat in RCCFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorderActive, not recruitingPhase 22023-09-01NCT03501381